The Long Read: Belgium – The Multifaceted
Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the mighty neighbouring pharmaceutical powerhouses of Germany and France, one could easily be forgiven for overlooking Belgium’s…
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.
Open Science
Allergan is an industry leader in Open Science, the Company’s R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.
16,000 Employees
Our Company’s success is powered by our more than 16,000 global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
100 Countries
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.
Contact
20 Pasir Panjang Road
Mapletree Business City
West Building, #09-25
Singapore 117439
+65 6747 7077
Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the mighty neighbouring pharmaceutical powerhouses of Germany and France, one could easily be forgiven for overlooking Belgium’s…
In 2020 PharmaBoardroom sat down with several key stakeholders in Belgian pharma to discuss company strategy, the Belgian healthcare landscape at large, and the country’s role within the wider European…
Javier Aracil, country manager of Allergan in Belgium and Luxembourg, introduces the priorities and objectives as he set as he entered his first country manager position coming from holding key…
2019 was a landmark year for the Chinese healthcare industry.* Since the publication of the ‘Healthy China 2030’ blueprint in 2016 by the Chinese government, the entire sector has been…
Adriana Stara, general manager Central Europe & Baltics at Allergan, explains how her previous experiences have prepared her to drive Allergan’s business in the region. Stara also delves into Allergan’s…
Within the industry, Allergan already stands out for the interesting composition of its portfolio. For China President White Wang, this was precisely the attraction. He enthuses, “Allergan is truly a…
Jose Viera-Colon, Region Director Caribbean for Allergan, highlights the opportunities and obstacles related to leading the company’s commercial operations in Puerto Rico and countries like the Dominican Republic. He also…
An exclusive interview with Jason Smith, SVP (Asia Pacific, Middle East and Africa); Gerry Muhle, VP (International Medical Aesthetics); and White Wang, China President, of Allergan, at the inauguration ceremony…
White Wang, president of Allergan China, shares the uniqueness of Allergan as a diversified company covering traditional pharmaceuticals and medical aesthetics; the milestones of his first year, with major projects…
Global medical aesthetics market leader Allergan is investing heavily in the Chinese city of Chengdu and has launched a number of initiatives there, including a global consumer experience centre, an…
Fernando Álvarez, director general of Allergan Iberia, highlights the market’s shift towards more holistic innovation and the company’s main growth drivers, especially in the field of aesthetics. Furthermore, he touches…
The last few years have witnessed the advent of a highly disruptive business model within the heart of the pharma world that fundamentally reconsiders the manner in which R&D is…
See our Cookie Privacy Policy Here
